Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Training program for DATA managers in hematopoietic cell transplantation and advanced cell therapy: A nine-year overview from Brazil

Cinthya Da Silva, Anderson João Simione, Flavia da Costa, Heliz Neves, Adriana Seber, Nelson Hamerschlak, Carmem Bonfim, Afonso Vigorito, Mary Flowers, Marcelo Pasquini, Fernando Barroso Duarte

Blood (2025) 146 (Supplement 1): 4647.

https://doi.org/10.1182/blood-2025-4647

Published: 2025

Journal Articles

Ultra high-risk multiple myeloma with early mortality despite quad-class and BCMA-directed therapies: Clinical and molecular insights

Binod Dhakal, Maria Hintzke, Othman Akhtar, Jamila Mammadova, Adetola Kassim, Marcelo Pasquini, Meera Mohan, Ravi Kishore Narra, Sabarinath Radhakrishnan, Fumou Sun, Anita D'Souza, Maher Albitar, Bhagirathbhai Dholaria

Blood (2025) 146 (Supplement 1): 2240.

https://doi.org/10.1182/blood-2025-2240

Published: 2025

Journal Articles

Immune restoration in long-term myeloma survival revealed by single-cell RNA-sequencing

Khanmi Kasomva, Kirthi Pulakanti, Josiah Murray, Kritika Yadav, Ravi Narra, Marcelo Pasquini, Anita D'Souza, Meera Mohan, Othman Akhtar, Deepak Parashar, Fumou Sun, Siegfried Janz, Binod Dhakal, Sridhar Rao

Blood (2025) 146 (Supplement 1): 5716.

https://doi.org/10.1182/blood-2025-5716

Published: 2025

Journal Articles

CD19-directed CAR T-cell therapy for B-cell lymphoid malignancies is safe and effective in people living with HIV (PWH) – a matched cohort analysis by the center for international blood and marrow transplant research (CIBMTR) and the AIDS malignancy consortium (AMC)

Stefan Barta, Ariela Noy, Kwang Woo Ahn, Jinalben Patel, Tiffany Hunt, Uroosa Ibrahim, Robert Baiocchi, Deukwoo Kwon, Marcelo Pasquini, Richard Ambinder

Blood (2025) 146 (Supplement 1): 955.

https://doi.org/10.1182/blood-2025-955

Published: 2025

Journal Articles

Comparison of clinical outcomes in multiple myeloma patients treated with chimeric antigen receptor (CAR)-T cell therapy across clinical trials: Intention-to-treat vs. per-protocol analyses

Abhishek Janardan, Pranav Jumin, Abigail Thorgerson, Ravi Kishore Narra, Othman Akhtar, Sabarinath Radhakrishnan, Marcelo Pasquini, Binod Dhakal, Anita D'Souza, Meera Mohan

Blood (2025) 146 (Supplement 1): 2800.

https://doi.org/10.1182/blood-2025-2800

Published: 2025

Journal Articles

Low conversion rates to minimal residual disease (MRD) negativity despite improved IMWG responses with lenalidomide-isatuximab maintenance after autologous stem cell transplant (ASCT) in multiple myeloma.

Meera Mohan, Aniko Szabo, Ravi Kishore Narra, Catharine Skoog, Areyl Goff, Binod Dhakal, Othman Akhtar, Marcelo Pasquini, Sabarinath Radhakrishnan, Sridhar Rao, Subramaniam Malarkannan, Carolina Schinke, Leo Rasche, Anita D'Souza

Blood (2025) 146 (Supplement 1): 5758.

https://doi.org/10.1182/blood-2025-5758

Published: 2025

Journal Articles

Sustained remission following limited duration of bispecific antibody therapy in patients with relapsed/refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 5757.

https://doi.org/10.1182/blood-2025-5757

Published: 2025

Journal Articles

Efficacy and safety of frail adults treated with ciltacabtagene autoleucel in the real-world: A CIBMTR analysis

Blood (2025) 146 (Supplement 1): 133.

https://doi.org/10.1182/blood-2025-133

Published: 2025

Journal Articles

High tolerability and favorable early outcomes with full-dose lenalidomide in older adults with newly diagnosed multiple myeloma on triplet and quadruplet therapies

Stephanie Yohay, Soyoung Kim, Mingqian Lin, Temitope Oloyede, Ravi Narra, Sabarinath Radhakrishnan, Meera Mohan, Binod Dhakal, Marcelo Pasquini, Anita D'Souza, Othman Akhtar

Blood (2025) 146 (Supplement 1): 6360.

https://doi.org/10.1182/blood-2025-6360

Published: 2025

Journal Articles

Real-world effectiveness and safety outcomes by age, comorbidities, and frailty among relapsed or refractory (R/R) Mantle Cell Lymphoma (MCL) patients treated with brexucabtagene autoleucel (brexu-cel)

Amer Beitinjaneh, Supriya Gupta, Fateeha Furqan, John Baird, Wen-Kai Weng, Caron Jacobson, Soyoung Kim, Zhongyu Feng, Babatunde Adedokun, Jiali Yan, Qian Huang, Kenny Hu, Timothy Best, Ioana Kloos, Grace Lee, Mehdi Hamadani, Marcelo Pasquini, Frederick Locke

Blood (2025) 146 (Supplement 1): 3606.

https://doi.org/10.1182/blood-2025-3606

Published: 2025

Journal Articles

Molecular profiling and kinetics of circulating multiple myeloma cells (CMMCs) predict resistance to bispecific antibodies (BsAbs) in relapsed and/or refractory multiple myeloma (RRMM)

Blood (2025) 146 (Supplement 1): 4012.

https://doi.org/10.1182/blood-2025-4012

Published: 2025

Journal Articles

Outcomes of HLA-matched unrelated versus haploidentical hematopoietic cell transplantation in acute leukemia: A multicenter observational study in Brazil facilitated by the CIBMTR

Blood (2025) 146 (Supplement 1): 5981.

https://doi.org/10.1182/blood-2025-5981

Published: 2025

Journal Articles

Real-world effectiveness and safety outcomes by age, comorbidity, frailty, and treatments prior to infusion in relapsed or refractory (R/R) follicular lymphoma patients treated with axicabtagene ciloleucel

Aung Tun, Matthew Frank, Madiha Iqbal, Alex Herrera, Mehdi Hamadani, Waleska Pérez, Soyoung Kim, Babatunde Adedokun, Constance Lau, Kenny Hu, Timothy Best, Olga Nikolajeva, Grace Lee, Marcelo Pasquini, Caron Jacobson

Blood (2025) 146 (Supplement 1): 5356.

https://doi.org/10.1182/blood-2025-5356

Published: 2025

Journal Articles

The brazilian registry of hematopoietic cell transplantation and cellular therapy: A MODEL of collaborative progress and DATA management leadership

Cinthya Da Silva, Anderson Simione, Afonso Vigorito, Nelson Hamerschlak, Carmem Bonfim, Mary Flowers, Adriana Seber, Antonio de Macedo, Heliz Neves, Marcelo Pasquini, Fernando Barroso Duarte

Blood (2025) 146 (Supplement 1): 8212.

https://doi.org/10.1182/blood-2025-8212

Published: 2025

Journal Articles

Outpatient (OP) use of lisocabtagene maraleucel (liso-cel) in patients (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): Real-world data from the CIBMTR registry

Krish Patel, Matthew Lunning, Konstantinos Sdrimas, Minoo Battiwalla, Uttam Rao, Yi Lin, Sami Ibrahimi, Jennifer L. Crombie, Sairah Ahmed, Iris Isufi, Matthew Frigault, David Bernasconi, Debasmita Roy, Marcelo Pasquini, Bradley D. Hunter

Blood (2025) 146 (Supplement 1): 5482.

https://doi.org/10.1182/blood-2025-5482

Published: 2025

Journal Articles

T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy

Blood (2025) 146 (7): 834–846.

https://doi.org/10.1182/blood.2025028833

Published: 2025

Includes: Supplemental data

Journal Articles

Racial Disparities in Autologous Stem Cell Transplant Utilization in Multiple Myeloma Persist Despite Referral to a Transplant Center

James Fan Wu, Noel Estrada-Merly, Binod Dhakal, Meera Mohan, Ravi Kishore Narra, Marcelo Pasquini, Jean Esselmann, Areyl Goff, Catherine E. Skoog, Anita D'Souza

Blood (2023) 142 (Supplement 1): 7346.

https://doi.org/10.1182/blood-2023-174279

Published: 2023

Journal Articles

Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US)

Blood (2023) 142 (Supplement 1): 104.

https://doi.org/10.1182/blood-2023-180242

Published: 2023

Journal Articles

Real World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 1027.

https://doi.org/10.1182/blood-2023-181762

Published: 2023

Journal Articles

Real-World Outcomes of Brexucabtagene Autoleucel (Brexu-cel) for Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL): A CIBMTR Subgroup Analysis of High-Risk Characteristics

Blood (2023) 142 (Supplement 1): 107.

https://doi.org/10.1182/blood-2023-179269

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Training program for DATA managers in hematopoietic cell transplantation and advanced cell therapy: A nine-year overview from Brazil

Ultra high-risk multiple myeloma with early mortality despite quad-class and BCMA-directed therapies: Clinical and molecular insights

Immune restoration in long-term myeloma survival revealed by single-cell RNA-sequencing

CD19-directed CAR T-cell therapy for B-cell lymphoid malignancies is safe and effective in people living with HIV (PWH) – a matched cohort analysis by the center for international blood and marrow transplant research (CIBMTR) and the AIDS malignancy consortium (AMC)

Comparison of clinical outcomes in multiple myeloma patients treated with chimeric antigen receptor (CAR)-T cell therapy across clinical trials: Intention-to-treat vs. per-protocol analyses

Low conversion rates to minimal residual disease (MRD) negativity despite improved IMWG responses with lenalidomide-isatuximab maintenance after autologous stem cell transplant (ASCT) in multiple myeloma.

Sustained remission following limited duration of bispecific antibody therapy in patients with relapsed/refractory multiple myeloma

Efficacy and safety of frail adults treated with ciltacabtagene autoleucel in the real-world: A CIBMTR analysis

High tolerability and favorable early outcomes with full-dose lenalidomide in older adults with newly diagnosed multiple myeloma on triplet and quadruplet therapies

Real-world effectiveness and safety outcomes by age, comorbidities, and frailty among relapsed or refractory (R/R) Mantle Cell Lymphoma (MCL) patients treated with brexucabtagene autoleucel (brexu-cel)

Molecular profiling and kinetics of circulating multiple myeloma cells (CMMCs) predict resistance to bispecific antibodies (BsAbs) in relapsed and/or refractory multiple myeloma (RRMM)

Outcomes of HLA-matched unrelated versus haploidentical hematopoietic cell transplantation in acute leukemia: A multicenter observational study in Brazil facilitated by the CIBMTR

Real-world effectiveness and safety outcomes by age, comorbidity, frailty, and treatments prior to infusion in relapsed or refractory (R/R) follicular lymphoma patients treated with axicabtagene ciloleucel

The brazilian registry of hematopoietic cell transplantation and cellular therapy: A MODEL of collaborative progress and DATA management leadership

Outpatient (OP) use of lisocabtagene maraleucel (liso-cel) in patients (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): Real-world data from the CIBMTR registry

T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy

Racial Disparities in Autologous Stem Cell Transplant Utilization in Multiple Myeloma Persist Despite Referral to a Transplant Center

Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US)

Real World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma

Real-World Outcomes of Brexucabtagene Autoleucel (Brexu-cel) for Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL): A CIBMTR Subgroup Analysis of High-Risk Characteristics

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only